Wechselwirkungen · Kineret
Kineret 100 mg/0.67 ml solution for injection in pre-filled syringe. · Abschnitt 4.5 · PDF-Seite 8
HOS-108743 · Präparat HOS-093075
Cytochrome P450 Substrates The formation of CYP450 enzymes is suppressed by increased levels of cytokines (e.g., IL-1) during chronic inflammation. Thus, it may be expected that for an IL-1 receptor antagonist, such as anakinra, the formation of CYP450 enzymes could be normalized during treatment. This would be clinically relevant for CYP450 substrates with a narrow therapeutic index (e.g. warfarin and phenytoin). Upon start or end of Kineret treatment in patients on these types of medicinal products, it may be relevant to consider therapeutic monitoring of the effect or concentration of these products and the individual dose of the medicinal product may need to be adjusted.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenytoin (HOS-084531) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-15T12:46:00Z · SHA-256 53a0a98f576dc350e42d4cc85e11cf9eeb4b97cf7707add713e0c1a596152e85 · Passage 9950adeb7b4496ab06c21fb6e6726a65b93abc3dd4d6b5704685fda5493496fc · Zeichen 873–1556 im Abschnitt